LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

AZN

188.47

+3.03%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

AZN

188.47

+3.03%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

AZN

188.47

+3.03%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

AZN

188.47

+3.03%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

AZN

188.47

+3.03%↑

Начало・Списък с акции・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Затворен

13.99

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

13.99

Максимум

13.99

Ключови измерители
By Trading Economics
Приходи	4.2M -23M
Служители	83
EBITDA	6.6M -23M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	-4.43% downside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	418M 1B
Предишно отваряне	13.99
Предишно затваряне	13.99

Ventyx Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

12.03.2026 г., 23:12 ч. UTC

Горещи акции

Stocks to Watch: Adobe, Mission Produce, Buzzfeed, Ulta

12.03.2026 г., 22:15 ч. UTC

Печалби

Wheaton Precious Metals Logs Higher 4Q Net Income, Boosts Dividend 18%

12.03.2026 г., 21:42 ч. UTC

Значими събития в новините

Stryker Says Cyberattack Disruption Is Continuing

12.03.2026 г., 21:29 ч. UTC

Значими събития в новините

Correction to War in Iran May Upend Brazil Central Bank's Plans Article

12.03.2026 г., 21:27 ч. UTC

Печалби

Adobe CEO to Depart as AI Boosts Sales -- Update

12.03.2026 г., 20:46 ч. UTC

Печалби

Adobe Posts Higher Sales With CEO Set to Depart

12.03.2026 г., 20:21 ч. UTC

Значими събития в новините

Soybean Futures Higher on Instability in Iran --Daily Grain Highlights

12.03.2026 г., 23:57 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Ongoing Middle East Conflict -- Market Talk

12.03.2026 г., 23:38 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

12.03.2026 г., 23:38 ч. UTC

Пазарно говорене

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

12.03.2026 г., 22:13 ч. UTC

Печалби

Orient Overseas: Tariff Measures, Trade Tensions Weighed on Results >0316.HK

12.03.2026 г., 22:13 ч. UTC

Печалби

Orient Overseas: Middle East Situation Have Added to Future Uncertainity >0316.HK

12.03.2026 г., 22:13 ч. UTC

Печалби

Orient Overseas: Charter Market Remains Exceptionally Tight With Vessels in Short Supply >0316.HK

12.03.2026 г., 22:13 ч. UTC

Печалби

Orient Overseas 2025 Rev $9.72B Vs. $10.70B >0316.HK

12.03.2026 г., 22:13 ч. UTC

Печалби

Orient Overseas 2025 Net $1.51B Vs. Net $2.58 >0316.HK

12.03.2026 г., 22:13 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

12.03.2026 г., 22:13 ч. UTC

Пазарно говорене

Печалби

Adobe Says Customers Want to Try AI Products for Free First -- Market Talk

12.03.2026 г., 21:16 ч. UTC

Придобивния, сливания и поглъщания

Alexander & Baldwin: JV Formed by Affil of MW Group and Funds Affiliated With Blackstone and DivcoWest Completed Acquisition of All Outstanding A&B Common Shrs >ALEX

12.03.2026 г., 21:04 ч. UTC

Печалби

Adobe Earnings Beat Is Overshadowed by CEO Departure. The Stock Is Sliding. -- Barrons.com

12.03.2026 г., 21:02 ч. UTC

Печалби

Wheaton Precious Metals 4Q Adj EPS $1.22 >WPM

12.03.2026 г., 21:02 ч. UTC

Печалби

Wheaton Precious Metals 4Q Sales $865M >WPM

12.03.2026 г., 21:02 ч. UTC

Печалби

Wheaton Precious Metals 4Q Net $558.3M >WPM

12.03.2026 г., 21:02 ч. UTC

Печалби

Wheaton Precious Metals 4Q EPS $1.23 >WPM

12.03.2026 г., 20:57 ч. UTC

Пазарно говорене

Значими събития в новините

No Need For Canada Rate Increases Amid Jump in Bond Yields -- Market Talk

12.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

12.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

12.03.2026 г., 20:15 ч. UTC

Придобивния, сливания и поглъщания

Eaton Completes Acquisition Of Leading Liquid-cooling Solutions Provider Boyd Thermal, Creating An Industry-leading Grid-to-chip Solution For Data Centers >ETN

12.03.2026 г., 20:10 ч. UTC

Печалби

Adobe Sees 2Q Rev $6.43B-$6.48B >ADBE

12.03.2026 г., 20:05 ч. UTC

Печалби

Adobe 1Q Rev $6.4B >ADBE

12.03.2026 г., 20:05 ч. UTC

Печалби

Adobe Sees 2Q Adj EPS $5.80-Adj EPS $5.85 >ADBE

Сравнение с други в отрасъла

Ценова промяна

Ventyx Biosciences Inc Прогноза

Ценова цел

By TipRanks

-4.43% надолу

12-месечна прогноза

Среден 13.38 USD -4.43%

Висок 14 USD

Нисък 9 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Ventyx Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Ventyx Biosciences Inc през последните 3 месеца.

Финанси

Относно Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.